Cue Biopharma (NASDAQ:CUE) Trading 0.7% Higher - Still a Buy?

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) traded up 0.7% on Monday . The stock traded as high as $0.71 and last traded at $0.70. 72,337 shares traded hands during trading, a decline of 82% from the average session volume of 406,223 shares. The stock had previously closed at $0.70.

Cue Biopharma Stock Up 1.6%

The company has a market cap of $59.98 million, a price-to-earnings ratio of -1.19 and a beta of 1.43. The business has a fifty day simple moving average of $0.69 and a 200 day simple moving average of $0.96.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.42 million during the quarter, compared to analysts' expectations of $0.90 million. Cue Biopharma had a negative net margin of 507.87% and a negative return on equity of 228.43%. Equities analysts anticipate that Cue Biopharma, Inc. will post -0.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Cue Biopharma

Several large investors have recently added to or reduced their stakes in CUE. Geode Capital Management LLC boosted its position in shares of Cue Biopharma by 24.1% in the 4th quarter. Geode Capital Management LLC now owns 631,281 shares of the company's stock valued at $688,000 after purchasing an additional 122,454 shares during the period. Bank of America Corp DE raised its stake in shares of Cue Biopharma by 35.6% in the 4th quarter. Bank of America Corp DE now owns 324,315 shares of the company's stock valued at $354,000 after acquiring an additional 85,113 shares in the last quarter. Stifel Financial Corp raised its stake in shares of Cue Biopharma by 8.8% in the 4th quarter. Stifel Financial Corp now owns 211,361 shares of the company's stock valued at $230,000 after acquiring an additional 17,139 shares in the last quarter. Northern Trust Corp increased its position in Cue Biopharma by 50.5% in the 4th quarter. Northern Trust Corp now owns 208,206 shares of the company's stock worth $227,000 after buying an additional 69,892 shares during the period. Finally, HighTower Advisors LLC increased its position in Cue Biopharma by 54.0% in the 4th quarter. HighTower Advisors LLC now owns 128,284 shares of the company's stock worth $140,000 after buying an additional 45,000 shares during the period. 35.04% of the stock is owned by institutional investors and hedge funds.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.